ND-0612 by Mitsubishi Tanabe Pharma for Parkinson’s Disease: Likelihood of Approval

[Farooqji]

ND-0612 is under development as an adjunct to oral levodopa for the treatment of moderate to severe Parkinson's disease. The drug candidate is a liquid fixed dose combination of levodopa and carbidopa administered through a patch-pump or belt pump to deliver controlled dose continuously as subcutaneous infusion. It is formulated as both high dose (ND-0612H) and low dose (ND-0612L) liquid formulation. The drug candidate acts by targeting dopa decarboxylase and dopaminergic receptors (D1, D2, D3, D4 and D5).

pharmaceutical-technology.c...

[Juliegrace]

Similar to the Abbvie product, which was rejected by the FDA because of something to do with the pump. It was supposed to be available late 2023, but now is expected to be approved in 2024.